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Methods: Atherectomy probes from 17 patients with coronary ISR (n=10; time post
stenting 5±3 months) and with peripheral ISR (n=7; 7±3 months) versus those from 10
patients with primary lesions were immunohistochemically examined for the presence of
the determinants CD34, AC133, S100, GFAP, NSE, NGFR and α-smooth muscle (SM)
actin followed by computer-assisted morphometry.
Results: ISR probes demonstrated pronounced hypercellularity (942±318 cells/mm2)
compared to primary lesions (347±120 cells/mm2, P<0.001). α-SM actin positive cells
occupied 67% of intimal cells in ISR. Expression of endothelial progenitor cells (EPCs;
CD34: 7.1±2.5% positive/total cells vs. 0.6±0.7%, P<0.001; AC133: 7.0±3.4% vs.
1.0±0.7%, P<0.001), dendritic cells (DCs; S100: 9.8±5.6% vs. 1.4±1.1%, P<0.001) and
neural-crest derived cells (NCCs; GFAP: 7.9±2.4% vs. 3.1±1.0%; NSE: 4.4±2.6% vs.
1.3±1.6%; NGFR: 4.2±2.5% vs. 1.1±0.7%; each P<0.001) was significantly increased in
ISR compared to primary lesions. Importantly, double immunostaining did not demon-
strate α-SM actin positive cells exhibiting markers of EPCs, DCs or NCCs. With respect
to EPC immunolabelling, AC133 could be detected in a subset of CD34 positive cells,
whereas all cells stained by AC133 also expressed the CD34 antigen. Quantitatively,
both EPC marker proteins revealed a significant correlation (r=0.57, P<0.01). Consis-
tently, there were a only few cells found in ISR atherectomy probes that demonstrated
coexpression of EPC, DC or NCC markers. Our data show residual 5-15% yet unidenti-
fied neointimal cells, that were not stained by any specific cell type marker used.
Conclusions: Bone-marrow and neural-crest derived cells, the most dendritic cells, are
consistently found in ISR, whereas α-SM actin positive cells constitute the largest intimal
cell pool. These data clearly indicate the presence of primarily extravascular cells in
human ISR.
1121-48 Preprocedural Plasma Levels of C-Reactive Protein and 
Interleukin-6 Do Not Predict Late Coronary 
Angiographic Restenosis After Elective Stenting
Amit Segev, Saleem Kassam, Christopher E. Buller, Herbert K. Lau, John D. Sparkes, 
Philip W. Connelly, Peter H. Seidelin, Madhu K. Natarajan, Eric A. Cohen, Bradley H. 
Strauss, St. Michael's Hospital, Toronto, ON, Canada, Vancouver Hospital and Health 
Sciences Centre, Vancouver, BC, Canada
Aims Inflammatory markers may serve as an important prognostic predictor in patients
with coronary heart diseases. In patients undergoing coronary interventions, it has been
shown that baseline C-reactive protein (CRP) could predict late adverse cardiac events
(clinical restenosis). However, only a few small studies have examined the relation with
angiographic restenosis. In a large number of patients, we examined whether baseline
plasma levels of CRP and IL-6 may predict late coronary angiographic restenosis after
elective coronary stenting.
Methods Pre-procedural plasma levels of CRP and IL-6 were measured in 216 patients
with stable angina pectoris undergoing elective coronary stenting who were included in
the MedStent and DISTINCT trials. Angiographic follow-up was performed in all patients
at 6 months. Angiographic restenosis was defined as diameter stenosis >50% by QCA at
6 months.
Results Baseline CRP levels were 6.45±0.78 mg/L versus 5.24±1.16 mg/L in the patent
and restenosis groups, respectively (p=0.64). IL-6 levels were 0.46±0.03 ng/L versus
0.40±0.07 ng/L in the patent and restenosis groups, respectively (p=0.50). CRP levels
were obtained again at the time of angiographic follow-up and were found to be similar in
both groups (2.89±0.29 mg/L versus 2.61±0.63 mg/L, p=0.72). Moreover, in a sub-group
of 43 patients, serial blood samples were obtained at several time points after the proce-
dure up to 6 months. Both CRP and IL-6 plasma levels were increased significantly in
response to the procedure. CRP levels peaked at 3 days (11.27±1.53 mg/L versus
4.26±0.72 mg/L at baseline, p<0.001). IL-6 levels reached maximum values after 24
hours (1.08±0.14 ng/L versus 0.53±0.08 ng/L at baseline, p<0.001). However, in this sub-
group of patients, neither peak CRP nor IL-6 levels were found to predict late angio-
graphic restenosis.
Conclusion Coronary stenting is associated with transient increases in both CRP and
IL-6 levels. However, pre-procedural CRP and IL-6 levels do not predict late coronary
angiographic restenosis.
1121-49 Homocysteine Levels and Methylenetetrahydrofolate 
Reductase Polymorphisms Are Not Associated With 
Restenosis After Coronary Artery Stenting
Werner Koch, Marc Burghartz, Harald Lengnick, Petra Hoppmann, Siegmund Braun, 
Klaus Kölling, Albert Schömig, Adnan Kastrati, Deutsches Herzzentrum München, 
Munich, Germany
Background: Elevated levels of plasma homocysteine have been associated with athero-
thrombotic diseases.Two polymorphisms, 677C/T and 1298A/C, of methylenetetrahydro-
folate reductase (MTHFR) interfere with enzyme activity and, therefore, may influence
homocysteine levels. We examined the possibility that elevated homocysteine and the
polymorphisms of MTHFR are associated with restenosis and adverse clinical outcomes
after stenting in coronary arteries.
Methods: The study population consisted of 800 patients with symptomatic coronary
artery disease who were treated with stent implantation. Angiographic restenosis (50%
or greater diameter stenosis at 6-month follow-up) and clinical restenosis (need for target
vessel revascularization during the first year after stenting) were evaluated.
Results: Six-month follow-up angiography was done in 601 patients (75.1%). The rates of
angiographic or clinical restenosis were not significantly different between patients with
low or high homocysteine levels or among the genotypes of the MTHFR polymorphisms
(Table). Late lumen loss and loss index were not associated with homocysteine levels or
the MTHFR genotypes (Table). The one-year incidence of death or MI was not depen-
dent on homocysteine concentrations or the genotypes (Table).
Conclusions: Our results suggest that elevated homocysteine levels or the MTHFR poly-
morphisms 677C/T and 1298A/C are not associated with restenosis and adverse clinical
outcomes after stenting in coronary arteries.
1121-50 Peroxisome Proliferator-Activated Receptor Gamma 
Gene Polymorphisms and Risk of Restenosis After 
Coronary Artery Stenting in Patients With Diabetes
Werner Koch, Vanessa Jung, Elena Michou, Olga Gorchakova, Klaus Tiroch, Nicolas von 
Beckerath, Albert Schömig, Adnan Kastrati, Deutsches Herzzentrum München, Munich, 
Germany
Background: Several lines of evidence suggest that activation of peroxisome prolifera-
tor-activated receptor gamma (PPARγ) may interfere with restenosis. Polymorphisms of
the PPARγ gene were found to be associated with coronary artery disease and diabetes.
We examined the role of the 34C/G and 1431C/T polymorphisms of the PPARγ gene in
restenosis after stenting in patients with diabetes.
Methods: The study population consisted of 752 diabetic patients with symptomatic cor-
onary artery disease who were treated with stenting. Restenosis was defined as a 50%
or greater diameter stenosis six months after the intervention. Clinical outcome mea-
sures (death, myocardial infarction, restenosis-driven reintervention) were evaluated dur-
ing the first year after the intervention. For analysis, patients homozygous for the
common allele were compared with the carriers of the rare allele.
Results: Restenosis rates and continuous measures of restenosis (late lumen loss, loss
index) were not significantly different between the PPARγ genotype groups (Table). In
addition, the one-year incidences of death or myocardial infarction and reintervention
were not significantly different between the groups (Table).
Conclusions: Our results suggest that the PPARγ gene polymorphisms 34C/G and
1431C/T are not associated with restenosis and adverse clinical outcomes after coronary
artery stenting in diabetic patients.
1121-51 SU11218, a Platelet-Derived Growth Factor Receptor 
and Vascular Endothelial Growth Factor Receptor 2 
Inhibitor Blocks Adventitial Angiogenesis and Prevents 
Intimal Hyperplasia After Coronary Stenting in a Porcine 
Model
Asim N. Cheema, Tony S. Hong, Jennifer Dietrich, David Holdsworth, Ken Lipson, 
Bradley H. Strauss, St. Michael's Hospital, Toronto, ON, Canada, John P. Robarts 
Research Institute, London, ON, Canada
Background: Balloon angioplasty has been shown to produce an angiogenic response in
the arterial adventitia, which is associated with restenosis in the injured segment. We
hypothesized that stenting will result in a similar but more prominent adventitial angio-
genic response and inhibition of this angiogenic response with a tyrosine kinase inhibitor
will prevent intimal hyperplasia and restenosis after coronary stenting.
Methods: We performed coronary stenting of the left circumflex artery in 20 Yorkshire
pigs. Pigs were treated with placebo or SU11218, a tyrosine kinase receptor inhibitor that
blocks the activity of PDGFR and VEGFR2, which was administered subcutaneously (5
mg/kg) twice weekly for four weeks. Intravascular ultrasound was performed immediately
after stenting and at four weeks for determination of lumen and intimal cross sectional
areas. Adventitial microvessels were assessed ex vivo in the stented segments by micro-
scopic computed tomography at a resolution of 16 um.
Results: The mean plasma levels for SU 11218 were 1.9-5.8ng/ml. At 4 weeks, arterial
stenting resulted in a marked angiogenic response in vascular adventitia and the number
of adventitial microvessels strongly correlated with the amount of instent intimal hyperpla-
Angiographic and clinical outcomes after coronary stenting according to MTHFR 
polymorphisms
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Angiographic restenosis 
rate (%)
26.0 23.5 26.9 0.75 24.4 25.9 24.0 0.90
Clinical restenosis rate 
(%)
19.5 17.1 23.3 0.37 17.6 18.6 24.7 0.27
Late lumen loss (mm) 1.01 1.04 1.05 0.79 1.02 1.05 0.98 0.69
Loss index 0.60 0.65 0.63 0.71 0.63 0.61 0.68 0.70
Death or MI, 1y (%) 3.2 3.0 6.7 0.22 3.5 3.9 2.1 0.69
Angiographic and clinical outcomes after coronary stenting according to the 
PPARgamma polymorphisms
34CC 34CG + 
34GG
P 
value
1431CC 1431CT + 
1431TT
P 
value
Restenosis rate (%) 35.4 36.2 0.88 35.4 36.3 0.85
Late lumen loss (mm) 1.22 1.30 0.34 1.23 1.24 0.89
Loss index 0.43 0.44 0.74 0.43 0.44 0.80
Death or myocardial 
infarction, 1y (%)
8.3 8.6 0.89 8.0 9.7 0.46
Restenosis-driven 
reintervention, 1y (%)
16.6 14.9 0.60 16.8 14.5 0.47
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sia (r=0.57, p<0.001) as well as percent area stenosis (r=0.56, p<0.001). The mean inti-
mal cross sectional area was 2.47±1.67 in the control arteries compared to 0.52±0.52
(p<0.003) in the SU11218 treated arteries. The mean number of adventitial microvessels
in the stented segment was significantly decreased in SU11218 group (16.71±3.82 ver-
sus 24.86±9.76 in the control group, p< 0.001).
Conclusions: Coronary stenting results in a prominent angiogenic response in the arterial
adventitia that strongly correlates with the intimal hyperplasia and percent area stenosis.
The tyrosine kinase receptor inhibitor, SU11218, markedly inhibited both the adventitial
angiogenic response and in-stent hyperplastic response after stentingAngiogenic inhibi-
tors such as SU11218 may have important therapeutic implications for preventing in-
stent restenosis.
1121-52 Inhibition of In-Stent Restenosis in Porcine Coronary 
Arteries by Copper Chelation
Lazar Mandinov, Karen L. Moodie, Anna Mandinova, Zhenwu Zhuang, Thomas Maciag, 
Michael Simons, Ebo D. de Muinck, Maine Medical Center, Scarborough, ME, Dartmouth 
Hitchcock Medical Center, Lebanon, NH
Background: In-stent restenosis is a complex process mediated by inflammatory cytok-
ines and growth factors, which regulate inflammatory cells recruitment to the vessel wall
as well as vascular smooth muscle cell migration and proliferation. Since intracellular
copper metabolism plays a crucial role in the stress-induced release of FGF-1 and IL1α,
both of which are important for neointima development after vessel injury, we examined
the effect of tetrathiomolybdate (TTM), a clinically proven copper chelator, on in-stent
restenosis in a porcine stent model.
Methods: Seventeen stents were implanted in the left anterior descending coronary
artery of 17 male pigs using a stent to artery overstretch ratio of 1.2:1. Nine pigs (Gr.1)
were treated daily with 10 mg/kg TTM p.o. starting 14 days prior to stent implantation and
continuing until sacrifice at 28 days follow-up, whereas 8 pigs (Gr.2) served as controls.
The effect of TTM on in-stent restenosis was assessed by biplane quantitative coronary
angiography before and immediately after stenting as well as at 28 days follow-up. Serum
ceruloplasmin activity, an indirect indicator of total copper level, was measured weekly.
Results: The two groups were comparable regarding baseline data including animal age
and body weight, stent size, vessel reference diameter, and ceruloplasmin activity. Post-
interventional minimal lumen diameter and overstretch ratio were similar for both groups.
However, at 28 days follow-up, there was a marked difference of all parameters relevant
to the in-stent restenosis in favor of the TTM-treated group: minimal lumen diameter was
2.2±0.6 mm in Gr.1 vs. 1.5±0.4 mm in Gr.2, p<0.05 and diameter stenosis was 22±18%
in Gr.1 vs. 42±17% in Gr.2, p<0.05. During the entire follow-up period, ceruloplasmin
activity in the TTM group was significantly decreased from 50% to 80% (p<0.0001) of its
baseline level.
Conclusions: This study is the first to provide evidence that copper chelation by tetrathi-
omolybdate can markedly prevent in-stent restenosis. Our data also suggest that this
simple and inexpensive approach is a potential tool in the management of vascular rest-
enosis after percutaneous interventions in clinical settings.
1121-53 Long-Term Clinical Follow-Up After Diffuse In-Stent 
Restenosis
Hiroyoshi Yokoi, Kei Nishiyama, Shinichi Shirai, Kenji Ando, Takashi Yamada, Koyu 
Sakai, Jiro Ando, Masashi Iwabuchi, Hideyuki Nosaka, Masakiyo Nobuyoshi, Kokura 
Memorial Hospital, Kitakyushu, Japan
Background: Although diffuse in-stent restenosis (ISR) has been known to be refractory
to repeated percutaneous coronary intervention (PCI), long-term outcome of those
patients has not yet been established. Methods: To evaluate long-term (7-11yrs) clinical
outcome after ISR, follow-up (FU) information was analyzed in 78 patients (pts) or 78
lesions with Palmaz-Schatz stent ISR at 6-month FU quantitative angiography. According
to the angiographic appearance, ISR occurred diffusely (lesion length>10mm) in 34
pts(44%), focally inside the stent in 26 pts(33%) and focally at the stent border in 18
pts(23%). Repeat PCI was performed in 58 pts(74%). Recurrent restenosis in the diffuse
type (85%) were significantly higher than those in the focally intra-stent type (12%) and in
the border type (19%)(P=0.0001). Mean FU interval was 8.1+1.0 yrs among 57 surviving
pts. FU rate was 98% at 8 yrs. Results: Event-free survival (EFS) rates at 8 yrs were as
follows: cardiac death 92%, death 80%, death/myocardial infarction (MI)/coronary artery
bypass surgery (CABG) 67%, death/MI/CABG/target lesion PCI 14%, death/MI/CABG/
any PCI 6%. EFS rates (Death/MI/CABG) at 8 yrs in the diffuse type (68%) were similar
with in the focally intra-stent type (51%) and focally at the stent border type
(88%)(P=0.17). Conclusion: Although PCI for diffuse ISR was associated with very high
recurrent restenosis rates rather than the other types of ISR, long-term clinical outcome
at 7-11 yrs of FU were similar among the three groups. 
1121-54 Implications of the “Watermelon Seeding” Phenomenon 
During Coronary Interventions for In-Stent Restenosis 
Insights From the Restenosis Intrastent Balloon 
Angioplasty Versus Elective Stenting (RIBS) 
Randomized Trial
Manuel Gomez-Recio, Cesar Moris, Luis Insa, Isabel Calvo, Jose M. Hernández, Jose A. 
Bullones, Vasco Gama-Ribeiro, A. Leitao-Marques, Armando Bethencourt, Roman 
Lezaun, Juan Angel, Jose R. Lopez-Minguez, Maria J. Pérez-Vizcayno, Fernando 
Alfonso, For the Restenosis Intra-stent: Balloon angioplasty versus elective Stenting 
(RIBS), Investigators, Cardiovascular Institute-San Carlos University Hospital, Madrid, 
Spain
Background: The occurrence of balloon slippage (“watermelon seeding”) (WMS) during
treatment of patients with in-stent restenosis (ISR) has been described, but predisposing
factors and the potential implications of this phenomenon remain unknown. Methods: In
the Restenosis Intra-stent: Balloon angioplasty vs elective Stenting (RIBS) randomized
study, 450 patients with ISR were included. Of these, 42 patients (9%) presented WMS
during the procedure. Results: WMS was detected in 26 patients (12%) in the balloon
arm and 16 (7%) in the stent arm (p= 0.11). In the stent arm, WMS was only noticed dur-
ing balloon predilation, never during stent implantation. As compared with 408 patients
without WMS, patients with WMS tended to have more severe [% diameter stenosis
(79+13% vs 76+12%, p=0.08), TIMI flow 0-1 (21% vs 8%, p=0.01)] and diffuse (length
>15 mm: 48% vs 34%, p=0.08) ISR lesions. Patients with WMS required more balloon
inflations (5.7+2.2 vs 3.5+1.9, p<0.001), longer total inflation time (184+116 vs 150+106
seconds, p=0.04), and had more frequently cross-over to stenting or ended the proce-
dure with residual dissections (26% vs 14.5%, p=0.04) and eventually obtained poorer
acute results (minimal lumen diameter 2.35+0.5 vs 2.53+0.5 mm, p=0.03). In addition, at
6-month follow-up patients with WMS had a smaller minimal lumen diameter (1.26+0.7
vs 1.61+0.7mm, p= 0.007) and a higher restenosis rate (56% vs 37%, p=0.017). On
logistic regression analysis the WMS phenomenon emerged as an independent predictor
of recurrent restenosis (Adjusted RR 2.1, 95%CI 1.1-4.1, p=0.04). Conclusions: The
WMS phenomenon is frequently seen during treatment of patients with ISR. Long and
severe lesions appear to predispose to this technical problem that never occurs during
stent deployment. In patients with ISR, WMS is associated with poorer acute and long-
term angiographic results. 
1121-55 The Presence of Side Branches Impacts Periprocedural 
Enzyme Elevation and Clinical Outcome in Patients 
Undergoing Brachytherapy for In-Stent Restenosis
Pramod K. Kuchulakanti, Seung-Woon Rha, Andrew E. Ajani, Natalie Gevorkian, Ellen 
Pinnow, Rebecca Torguson, Augusto Pichard, Lowell F. Satler, Kenneth Kent, Joseph 
Lindsay, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Major side branch (diameter >1.5mm, SB) involvement within the lesion
subjected for Percutaneous Coronary Intervention (PCI) is known to be a contributing
factor for periprocedural cardiac enzyme elevation (CE). We aimed to assess the impact
of SB on CE and 6 month outcome in-patients undergoing brachytherapy for in-stent res-
tenosis. (ISR).
Methods: Retrospective analysis of the data of 248 consecutive patients with a single
vessel ISR with SB (Gp1, n=146) and without SB (Gp2, n=102) who underwent brachy-
therapy using both beta and gamma emitters was conducted. The procedural complica-
tions, CE, in-hospital course and 6 month clinical outcome were compared.
Results: The baseline patient and lesion characteristics were similar among the groups.
Procedural variables were similar except that stent usage was more in Gp1. Baseline
Creatine Phosphokinase (CPK)-MB levels were similar, but post procedure CPK-MB lev-
els were higher in Gp1. In hospital complications were similar between the two groups.
Six months follow up revealed higher restenosis and Major Adverse Cardiac Events
(MACE) in Gp1.
Conclusions: Presence of SB within the restenotic segment when treated with PCI and
brachytherapy is associated with higher preocedural CE and MACE at six months. Spe-
cial care should taken when treating ISR lesions with SB.
